ATE389659T1 - Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors - Google Patents

Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors

Info

Publication number
ATE389659T1
ATE389659T1 AT02740691T AT02740691T ATE389659T1 AT E389659 T1 ATE389659 T1 AT E389659T1 AT 02740691 T AT02740691 T AT 02740691T AT 02740691 T AT02740691 T AT 02740691T AT E389659 T1 ATE389659 T1 AT E389659T1
Authority
AT
Austria
Prior art keywords
ampa receptor
benzoxazepine derivatives
receptor stimulators
stimulators
benzoxazepine
Prior art date
Application number
AT02740691T
Other languages
English (en)
Inventor
Simon James Anthony Grove
Mingqiang Zhang
Mohammad Shahid
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE389659T1 publication Critical patent/ATE389659T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02740691T 2001-06-11 2002-06-05 Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors ATE389659T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01202215 2001-06-11

Publications (1)

Publication Number Publication Date
ATE389659T1 true ATE389659T1 (de) 2008-04-15

Family

ID=8180450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02740691T ATE389659T1 (de) 2001-06-11 2002-06-05 Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors

Country Status (29)

Country Link
US (2) US7307073B2 (de)
EP (1) EP1399450B1 (de)
JP (1) JP4435561B2 (de)
KR (1) KR100863255B1 (de)
CN (1) CN1257908C (de)
AR (1) AR036092A1 (de)
AT (1) ATE389659T1 (de)
AU (1) AU2002314144B2 (de)
BR (1) BR0210222A (de)
CA (1) CA2450274C (de)
CO (1) CO5550447A2 (de)
CZ (1) CZ300052B6 (de)
DE (1) DE60225689T2 (de)
EC (1) ECSP034891A (de)
ES (1) ES2301651T3 (de)
HR (1) HRP20031007A2 (de)
HU (1) HUP0400154A3 (de)
IL (2) IL158905A0 (de)
IS (1) IS2526B (de)
MX (1) MXPA03011563A (de)
NO (1) NO328705B1 (de)
NZ (1) NZ529670A (de)
PE (1) PE20030097A1 (de)
PL (1) PL366721A1 (de)
RU (1) RU2279434C2 (de)
SK (1) SK287150B6 (de)
TW (1) TWI232863B (de)
WO (1) WO2002100865A1 (de)
ZA (1) ZA200309382B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100864267B1 (ko) 2001-06-14 2008-10-20 엔.브이.오가논 AMPA 수용체의 양성 조절제로서의(피리도/티에노)-[f]-옥사제핀-5-온 유도체
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
MY160064A (en) * 2009-09-28 2017-02-15 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
FR2964969B1 (fr) 2010-09-16 2012-08-24 Servier Lab Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20150011554A1 (en) 2013-06-13 2015-01-08 Veroscience Llc Compositions and Methods for Treating Metabolic Disorders
EP3436021A4 (de) 2016-03-29 2019-11-06 RespireRx Pharmaceuticals Inc. Zusammensetzungen und verfahren zur behandlung von aufmerksamkeitsdefizitstörungen
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
TWI801517B (zh) 2018-03-12 2023-05-11 加拿大商愛彼特生物製藥公司 經取代的2-吡啶酮三環化合物、其類似物及其使用方法
CA3096687A1 (en) 2018-04-12 2019-10-17 Arbutus Biopharma Corporation Methods for preparing substituted pyridinone-containing tricyclic compounds
BR112021009770A2 (pt) 2018-11-22 2021-08-17 Fujian Cosunter Pharmaceutical Co., Ltd. forma cristalina de inibidor de antígeno de superfície de hepatite b
US20230218632A1 (en) * 2020-03-20 2023-07-13 Amathus Therapeutics, Inc. Cyclic sulfonamide derivatives as trap1 modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1238719A (de) 1968-11-01 1971-07-07
EP1367056A1 (de) 1992-07-24 2003-12-03 The Regents Of The University Of California Arzneimittel die den durch AMPA Rezeptoren vermittelten synaptischen Respons erhöhen
DK0801651T3 (da) 1995-01-06 2001-10-22 Hoffmann La Roche Hydroxymethyl-imidazodiazepiner og deres estere
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
CN1293665A (zh) * 1998-02-18 2001-05-02 神经研究公司 新化合物及其用作阳性ampa受体调节剂
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
CN1257908C (zh) 2006-05-31
HUP0400154A2 (hu) 2004-07-28
US20040171605A1 (en) 2004-09-02
CA2450274C (en) 2010-12-21
SK15182003A3 (sk) 2004-05-04
ES2301651T3 (es) 2008-07-01
CZ300052B6 (cs) 2009-01-21
EP1399450A1 (de) 2004-03-24
US7307073B2 (en) 2007-12-11
AR036092A1 (es) 2004-08-11
CZ20033376A3 (en) 2004-04-14
NO328705B1 (no) 2010-05-03
CN1514835A (zh) 2004-07-21
NZ529670A (en) 2006-02-24
PE20030097A1 (es) 2003-02-08
ZA200309382B (en) 2005-03-02
KR20040006030A (ko) 2004-01-16
HRP20031007A2 (en) 2005-10-31
HK1061858A1 (en) 2004-10-08
JP4435561B2 (ja) 2010-03-17
IL158905A (en) 2008-12-29
RU2279434C2 (ru) 2006-07-10
TWI232863B (en) 2005-05-21
IS7036A (is) 2003-11-13
CA2450274A1 (en) 2002-12-19
PL366721A1 (en) 2005-02-07
ECSP034891A (es) 2004-01-28
DE60225689T2 (de) 2008-07-17
CO5550447A2 (es) 2005-08-31
EP1399450B1 (de) 2008-03-19
BR0210222A (pt) 2004-04-13
IS2526B (is) 2009-07-15
SK287150B6 (sk) 2010-01-07
DE60225689D1 (de) 2008-04-30
WO2002100865A1 (en) 2002-12-19
IL158905A0 (en) 2004-05-12
KR100863255B1 (ko) 2008-10-15
NO20035486D0 (no) 2003-12-10
MXPA03011563A (es) 2004-03-18
HUP0400154A3 (en) 2007-05-02
JP2004533466A (ja) 2004-11-04
AU2002314144B2 (en) 2008-01-31
US20080139529A1 (en) 2008-06-12
US7504390B2 (en) 2009-03-17
RU2004100310A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60135239D1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE496032T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
ATE392416T1 (de) Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors
DE60021507D1 (de) Uracilverbindungen und deren Verwendung
DE60107603D1 (de) Pyrimidinverbindungen und deren verwendung als pestizide
ATE389659T1 (de) Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
DE60126614D1 (de) 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
ATE361295T1 (de) Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten
DE60311277D1 (de) Benzotriazabicyclische derivate und deren verwendung als beta-lactamaseinhibitoren und antibakterielle mittel
DE50004104D1 (de) Indolderivate und deren verwendung als 5ht2a liganden
DE60331160D1 (de) Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1399450

Country of ref document: EP